赫赛汀的用药指证：

Indications

Adjuvant Breast Cancer

Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer:

• As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
• With docetaxel and carboplatin
• As a single agent following multi-modality anthracycline-based therapy

* High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

Metastatic Breast Cancer

Herceptin is indicated:

• In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

目前的研究结果：对于Her-2阳性的乳癌患者，辅助使用赫赛汀有助于延长生存，以及延缓/防止复发。

任何药物都尤其副作用，赫赛汀的常见副作用是腹泻，一些非特异的感冒样症状等，但比较严重（虽然不那么常见）的副作用是心衰等心脏方面的疾病，所以需要定期做心脏方面的监测筛查。